OKYO Pharma Limited’s SEC filings document foreign-private-issuer reports on Form 6-K for a clinical-stage biopharmaceutical company with ordinary shares listed on Nasdaq. The disclosures cover urcosimod clinical and regulatory updates for neuropathic corneal pain, scientific-meeting materials, and descriptions of the company’s focus on inflammatory eye diseases and other ocular disorders.
The filing record also includes capital-structure and financing disclosures tied to Form F-3 registration statements, ordinary-share offerings, underwriter option exercises, and insider share purchases. These records present formal updates on the company’s securities, ownership activity, incorporated exhibits, and material announcements furnished under Exchange Act Rule 13a-16.
OKYO Pharma Limited, a Guernsey‑incorporated biotech listed on the Nasdaq Capital Market, reports on its fiscal year ended March 31, 2026 under IFRS, highlighting it remains a clinical‑stage company with no product revenue and a pipeline focused on ocular surface and corneal pain indications.
The lead candidate urcosimod (formerly OK‑101) is in mid‑stage development for neuropathic corneal pain and other anterior segment diseases, while OK‑201 is at an early stage. The company describes high clinical and regulatory failure risk, lengthy timelines and substantial uncertainty around ultimately achieving commercialization.
As of March 31, 2026, cash, cash equivalents and short‑term investments were $20.6 million, with a working capital surplus of $12.3 million, yet management expects significant ongoing losses and states it will need to raise substantial additional capital, potentially through dilutive equity or other financings, to fund research, trials, manufacturing arrangements and prospective commercialization. Extensive risk disclosures also cover dependence on third‑party manufacturers and CROs, intense competition in ocular disease, patent and trade‑secret challenges, pricing and reimbursement constraints, evolving US, UK and EU regulation (including GDPR), and potential product‑liability and cybersecurity exposures.
OKYO Pharma reports positive feedback from a U.S. FDA Type D meeting on its lead drug candidate, urcosimod, for neuropathic corneal pain (NCP). The agency aligned with a single-dose global Phase 3 pivotal trial, called NEPTUNE, and acknowledged a potential single-trial registration pathway, subject to successful results and continued review.
The NEPTUNE study is planned in the United States and Europe, enrolling about 111 patients in a 2:1 randomization of 0.05% urcosimod versus placebo. Urcosimod already has Fast Track designation, and OKYO plans to seek Breakthrough Therapy Designation to further accelerate development in this debilitating disease with no FDA-approved treatments.
OKYO Pharma Limited filed a report describing its participation in the Piper Sandler 2026 Virtual Ophthalmology Symposium. The company will join a fireside chat on July 9, 2026 at 8:30 AM, featuring CEO Robert J. Dempsey and Chief Medical Officer Flavio Mantelli.
OKYO is a clinical-stage biopharma company focused on innovative therapies for neuropathic corneal pain and inflammatory eye diseases. It recently completed a successful Phase 2 trial of its lead drug urcosimod in neuropathic corneal pain and plans a 150-patient Phase 2b/3 multiple-dose study.
OKYO Pharma Ltd filed a Form 3 for Chief Medical Officer Flavio Mantelli, disclosing his holdings of company share options. The filing lists four option positions over common stock, each tied to 187,500 underlying shares.
All options carry an exercise price of $1.96 per share and an expiration date in 2036. The options have scheduled exercise (vesting) dates in 2027, 2028, 2029, and 2030, showing when they become exercisable if conditions are met. This Form 3 records Mantelli’s existing derivative holdings rather than any new market transaction.
OKYO Pharma director Bernard Denoyer received an option grant for 3,500 shares of OKYO Pharma Ltd common shares. The options have an exercise price of $1.85 per share and are exercisable into 3,500 common shares. After this grant, Denoyer holds options on 35,190 shares in total. The options are scheduled to expire on June 8, 2036, indicating a long-dated, compensation-related award rather than an open-market share purchase or sale.
OKYO Pharma Ltd director John P. Brancaccio received a grant of options over 6,500 common shares at an exercise price of $1.85 per share. These options were awarded on June 8, 2026 and are scheduled to become exercisable on June 8, 2027, expiring on June 8, 2036. Following this compensation-related grant, Brancaccio holds options over 138,394 shares in total.
OKYO Pharma Ltd director Simon Willy Jules received a grant of options over 6,500 common shares at an exercise price of $1.85 per share. These options relate to common shares and increase his directly held derivative position to 135,502 options following the transaction. The options become exercisable on June 8, 2027 and are scheduled to expire on June 8, 2036, indicating a long-term, compensation-related award rather than an open-market share purchase or sale.
OKYO Pharma Ltd reported that Chief Financial Officer Keeren Rameshchandra Shah received a grant of options covering 40,000 common shares at an exercise price of $1.85 per share. These options are exercisable beginning on June 8, 2027 and expire on June 8, 2036. Following this award, the filing shows 544,819 derivative securities held directly, indicating this is a compensation-related grant rather than an open-market purchase.
OKYO Pharma Ltd director and 10% owner Gabriele M. Cerrone reported an indirect acquisition of 300,000 shares of common stock. The shares were received as a grant or award at a reference price of $1.72 per share and are held through Panetta Partners Limited.
Following this transaction, indirect holdings associated with Cerrone total 10,826,416 shares of OKYO Pharma common stock, indicating this was a relatively small addition to an already large position.
OKYO Pharma Ltd director Bernard Denoyer filed an initial ownership report showing multiple option grants over OKYO common stock. The options have exercise prices ranging from $1.46 to $2.13 per share and expire between 2033 and 2035. Examples include options over 3,750 underlying shares at $1.50 expiring in 2035 and options over 3,334 underlying shares at $1.46 expiring in 2034.